TimesSquare Capital Management LLC Has $27.22 Million Stake in Tarsus Pharmaceuticals, Inc. $TARS

TimesSquare Capital Management LLC increased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 24.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 332,446 shares of the company’s stock after purchasing an additional 64,941 shares during the period. TimesSquare Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $27,221,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Comerica Bank boosted its stake in Tarsus Pharmaceuticals by 470.0% in the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after purchasing an additional 705 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Tarsus Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock worth $169,000 after purchasing an additional 431 shares during the period. Osaic Holdings Inc. boosted its stake in Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after purchasing an additional 2,462 shares during the period. Valeo Financial Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at $209,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after buying an additional 2,782 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ:TARS opened at $62.82 on Tuesday. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The firm has a fifty day moving average of $66.85 and a two-hundred day moving average of $71.55. The firm has a market capitalization of $2.70 billion, a P/E ratio of -55.11 and a beta of 0.52.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The business had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. On average, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $26,130.00. Following the completion of the sale, the insider owned 23,308 shares of the company’s stock, valued at approximately $1,561,636. The trade was a 1.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $283,477.00. Following the completion of the sale, the general counsel directly owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. The trade was a 6.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 79,391 shares of company stock worth $5,432,035 in the last 90 days. 9.64% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They set an “outperform” rating and a $98.00 target price for the company. The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. HC Wainwright reissued a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research note on Monday, May 4th. Zacks Research lowered shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Guggenheim lifted their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.